Class Action Alleges Minerva Neurosciences Misled Stockholders About Clinical Trials for Schizophrenia Drug Candidate
December 10, 2020 A class action claims Minerva Neurosciences stockholders were misled by the company as to the outcome of clinical trials for a schizophrenia drug candidate.